November 24, 2020 – Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2

diabetes-type1

Please CLICK HERE to read the article, “Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2”

/ Uncategorized
  • Next Post
  • Previous Post
SIGN UP NOW

Click here to participate in a study

NRI CLINICS ARE CURRENTLY OPEN!
X